Yingchun Ye

Yingchun Ye

Auto-generated profile, based on publicly available information

Yingchun Ye

Southwest Medical University Public Center of Experimental Technology, School of Basic Medical Sciences Luzhou 646000

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
LLLin Li
Lin Li
LWLi Wang
Li Wang
QLQin Liu
Qin Liu
YYYingchun Ye
Yingchun Ye
QLQian Lei
Qian Lei
QYQing Yuan
Qing Yuan
Siglec-15, a member of the sialic acid–binding immunoglobulin-like lectins (Siglec) family, has emerged as a pivotal immunosuppressive mediator and a promising therapeutic target in cancer immunotherapy. This transmembrane glycoprotein orchestrates multifaceted biological processes, such as osteoclastogenesis regulation, bone remodeling, and tumor-associated macrophage-mediated T-cell immunosuppression. Notably, Siglec-15 exhibits nonredundant expression with PD-L1, suggesting its compensatory role in immune evasion mechanisms within a PD-L1–negative tumor microenvironment. This review delineates the molecular architecture of Siglec-15 and elucidates its pleiotropic regulatory mechanisms. Particular emphasis is placed on deciphering its immunomodulatory functions within tumor ecosystems while critically evaluating emerging therapeutic modalities targeting Siglec-15, spanning from preclinical validation to ongoing clinical trials.

31 July 2026 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
YWYao Wu
Yao Wu
MLMingjie Liao
Mingjie Liao
HCHan Chen
Han Chen
YYYingchun Ye
Yingchun Ye
XGXiyuan Guo
Xiyuan Guo
QYQing Yuan
Qing Yuan
Bispecific antibodies (BsAbs) have emerged as a promising therapeutic strategy in cancer immunotherapy, enabling simultaneous targeting of two distinct antigens to redirect immune effector cells, block compensatory pathways, and modulate the tumor immune microenvironment (TIME). Hundreds of BsAbs are currently in clinical trials, among which immune cell engagers (ICEs) demonstrate substantial therapeutic potential by bridging tumor cells and effector cells to enhance cytotoxic activity. However, the clinical translation of BsAbs is hampered by heterogeneous therapeutic responses, immune-related adverse events (irAEs), drug resistance, and inherent immunogenicity. In this review, we systematically dissect the applications of BsAbs in tumor immunotherapy, focusing on rational target combinations, underlying immunological mechanisms, and clinical therapeutic potential, while critically evaluating the advantages and limitations of representative BsAb modalities. We aim to address a key unresolved question: why some BsAb regimens achieve durable clinical efficacy (e.g., blinatumomab in hematological malignancies), whereas others show limited activity in solid tumors (e.g., vanucizumab). Through comparative mechanistic analysis, we clarify the critical trade-offs among therapeutic efficacy, systemic toxicity, and immunosuppressive barriers within the tumor microenvironment. To mitigate these translational bottlenecks, we summarize cutting-edge engineering approaches–including trispecific antibodies, prodrug-conjugated BsAbs, and proteolysis-targeting chimeras (PROTACs) — that optimize the balance between anti-tumor potency and off-target toxicity. This review provides a conceptual framework for advancing the translational development of BsAbs and guiding the rational design of next-generation precision cancer immunotherapies.